文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

SARS-CoV-2感染与呼吸机相关性下呼吸道感染发生率的关系:一项欧洲多中心队列研究

Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study.
PubMed 文献 · Intensive Care Med · 2021-01-03
一句话结论SARS-CoV-2肺炎患者呼吸机相关性下呼吸道感染发生率显著高于流感肺炎或无病毒感染患者,调整后sHR分别为1.60和1.7。

该欧洲36个ICU多中心回顾性队列纳入1576例有创机械通气>48h的成人患者,分为SARS-CoV-2肺炎组(568例)、流感肺炎组(482例)和无病毒感染组(526例)。VA-LRTI(含VAT和VAP)经临床、影像和定量微生物标准诊断,前瞻性识别。SARS-CoV-2组VA-LRTI累积发生率50.5%,显著高于流感组30.3%(调整sHR 1.60,95%CI 1.26-2.04)和无病毒感染组25.3%(调整sHR 1.7,95%CI 1.2-2.39)。革兰阴性杆菌占VA-LRTI的82%-89.7%,以铜绿假单胞菌、肠杆菌属和克雷伯菌属为主。

要点

  • SARS-CoV-2肺炎机械通气患者VA-LRTI发生率50.5%,显著高于流感肺炎30.3%(调整sHR 1.60,95%CI 1.26-2.04)。
  • SARS-CoV-2组VA-LRTI发生率亦显著高于无病毒感染组25.3%(调整sHR 1.7,95%CI 1.2-2.39)。
  • 革兰阴性杆菌占VA-LRTI的82%-89.7%,主要为铜绿假单胞菌、肠杆菌属和克雷伯菌属。
  • 研究为回顾性队列,作者指出残余混杂可能仍影响效应估计,需谨慎解读。
  • VA-LRTI诊断采用临床、影像和定量微生物标准,胸片由至少两名医生分析。

适用人群与场景

  • 36个欧洲ICU的成人患者,接受有创机械通气>48h,且ICU入科时存在SARS-CoV-2肺炎、流感肺炎或无病毒感染。

诊断标准与关键阈值

  • VA-LRTI包括呼吸机相关性气管支气管炎(VAT)和呼吸机相关性肺炎(VAP),采用临床、影像和定量微生物标准诊断。
  • 胸片由至少两名医生分析。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:欧洲多中心回顾性队列,36个ICU,纳入1576例成人有创机械通气>48h患者。
  • 分组:SARS-CoV-2肺炎组568例,流感肺炎组482例,无病毒感染组526例。
  • 主要终点:VA-LRTI累积发生率SARS-CoV-2组50.5%(287例),流感组30.3%(146例,调整sHR 1.60,95%CI 1.26-2.04),无病毒感染组25.3%(133例,调整sHR 1.7,95%CI 1.2-2.39)。
  • 微生物学:革兰阴性杆菌占VA-LRTI的82%-89.7%,主要为铜绿假单胞菌、肠杆菌属和克雷伯菌属。
  • 原文未提及关键次要终点和不良事件的具体结果。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:回顾性设计,作者指出残余混杂可能仍影响效应估计。

对床旁实践的改变

  • 对于SARS-CoV-2肺炎接受有创机械通气>48h的成人患者,应警惕VA-LRTI发生风险高于流感肺炎或无病毒感染患者。
  • VA-LRTI以革兰阴性杆菌为主,经验性抗感染方案需覆盖铜绿假单胞菌、肠杆菌属和克雷伯菌属。
  • 原文未提及具体抗菌药物剂量或疗程推荐。

指南或共识出处

  • Intensive Care Med:Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study.

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

PURPOSE: Although patients with SARS-CoV-2 infection have several risk factors for ventilator-associated lower respiratory tract infections (VA-LRTI), the reported incidence of hospital-acquired infections is low. We aimed to determine the relationship between SARS-CoV-2 pneumonia, as compared to influenza pneumonia or no viral infection, and the incidence of VA-LRTI.

METHODS: Multicenter retrospective European cohort performed in 36 ICUs. All adult patients receiving invasive mechanical ventilation > 48 h were eligible if they had: SARS-CoV-2 pneumonia, influenza pneumonia, or no viral infection at ICU admission. VA-LRTI, including ventilator-associated tracheobronchitis (VAT) and ventilator-associated pneumonia (VAP), were diagnosed using clinical, radiological and quantitative microbiological criteria. All VA-LRTI were prospectively identified, and chest-X rays were analyzed by at least two physicians. Cumulative incidence of first episodes of VA-LRTI was estimated using the Kalbfleisch and Prentice method, and compared using Fine-and Gray models.

RESULTS: 1576 patients were included (568 in SARS-CoV-2, 482 in influenza, and 526 in no viral infection groups). VA-LRTI incidence was significantly higher in SARS-CoV-2 patients (287, 50.5%), as compared to influenza patients (146, 30.3%, adjusted sub hazard ratio (sHR) 1.60 (95% confidence interval (CI) 1.26 to 2.04)) or patients with no viral infection (133, 25.3%, adjusted sHR 1.7 (95% CI 1.2 to 2.39)). Gram-negative bacilli were responsible for a large proportion (82% to 89.7%) of VA-LRTI, mainly Pseudomonas aeruginosa, Enterobacter spp., and Klebsiella spp.

CONCLUSIONS: The incidence of VA-LRTI is significantly higher in patients with SARS-CoV-2 infection, as compared to patients with influenza pneumonia, or no viral infection after statistical adjustment, but residual confounding may still play a role in the effect estimates.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Rouzé A, Martin-Loeches I, Povoa P, et al. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. Intensive Care Med. 2021. PMID: 33388794. doi:10.1007/s00134-020-06323-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。